Scarica l'app Stockscreener
1.70
2.30%
-0.04
Dopo l'orario di chiusura:
1.71
0.01
+0.59%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché OPK Giù?
Forum
Previsione
Opko Health Inc Borsa (OPK) Ultime notizie
Charles Schwab Investment Management Inc. Sells 714,949 Shares of OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
Phillip Md Et Al Frost Purchases 150,000 Shares of OPKO Health, Inc. (NASDAQ:OPK) Stock - MarketBeat
Entera Bio's Breakthrough: Oral Peptide Programs Show Promise as 2024 Results Reveal $21M War Chest - StockTitan
Here's Why You Should Retain OPKO Health Stock in Your Portfolio - Yahoo Finance
Zacks Research Weighs in on OPKO Health FY2027 Earnings - MarketBeat
OPKO Health Insider Ups Holding During Year - Simply Wall St
Quote - OPKO Health, Inc.
HC Wainwright Reaffirms "Buy" Rating for OPKO Health (NASDAQ:OPK) - MarketBeat
Best Buy, Las Vegas Sands, Globalstar, Opko Health, Agilent: Stock Moves Unveiled - MSN
OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Buys 200,000 Shares - MarketBeat
PRESS RELEASE ISSUED FEBRUARY 4, 2000 - OPKO Health, Inc.
Q2 EPS Estimates for OPKO Health Increased by HC Wainwright - MarketBeat
Chairman & CEO of OPKO Health Phillip Frost Buys More Stock - Yahoo Finance
H.C. Wainwright maintains Buy on Opko Health, $3 target By Investing.com - Investing.com Canada
OPKO Health, Entera Bio Partner on Oral Dual Agonist GLP-1 - Contract Pharma
Forecasting The Future: 6 Analyst Projections For OPKO Health - Benzinga
Opko and Entera focus on oral care for obesity and metabolic disorders - Yahoo Finance
Opko Health, Entera Bio sign agreement for oral GLP-1/glucagon dual agonist peptide - BioWorld Online
OPKO and Entera Link Up to Advance First Oral GLP-1/Glucagon Drug Into Clinic - BioSpace
OPKO and Entera Bio partner on oral obesity treatment By Investing.com - Investing.com Australia
Essential Planning LLC. Makes New $506,000 Investment in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
OPKO And Entera Bio Team Up For Game-Changing Obesity Pill - Finimize
OPKO Health, Entera Bio Collaborate To Develop Oral Dual GLP-1/Glucagon Therapy For Obesity - Nasdaq
Labcorp Is Buying BioReference Health’s Cancer Testing Business for $192 Million - Dealbreaker
OPKO and Entera partner to develop obesity pill - Reuters
Opko Health, Entera Bio to Collaborate on Tablet for Obesity, Metabolic and Fibrotic Disorders - MarketWatch
Entera Bio Collaborates with OPKO for Oral GLP-1/Glucagon - TipRanks
OPKO, Entera to Co-Develop Oral GLP-1/Glucagon Therapy for Obesity -March 17, 2025 at 08:38 am EDT - Marketscreener.com
OPKO and Entera Bio partner on oral obesity treatment - Investing.com India
OPKO Health and Entera Bio Enter into Collaboration - GlobeNewswire
Revolutionary Oral GLP-1 Obesity Treatment: OPKO and Entera Join Forces to Challenge Injectable Market - StockTitan
OPKO Health (NASDAQ:OPK) Earns Buy Rating from HC Wainwright - MarketBeat
OPKO Health (NASDAQ:OPK) Given "Outperform" Rating at Barrington Research - MarketBeat
Labcorp Is Buying BioReference Health’s Cancer Testing Business for $192M - MedCity News
Labcorp is Set to Acquire Select Assets of BioReference Health of OPK - MSN
OPKO Health (NASDAQ:OPK) Shares Gap UpStill a Buy? - MarketBeat
Tesla Stock Is Reaching a Breaking Point, Analyst Says. Plus, Vertical Aerospace, OPKO Health, and More. - Barron's
Is OPKO Health, Inc. (OPK) The Best Stock Under $3 to Buy Now? - Insider Monkey
0.80%
0.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):